α-galactosidase

Names

[ Name ]:
α-galactosidase

[Synonym ]:
Agalsidase
E.C. 3.2.1.22
alpha-Galactoside galactohydrolase
Melibiase
2-Quinoxalinecarbonyl chloride
quinoxaline-2-carbonyl chloride
alpha-D-Galactosidase
alpha-GAL 600L
alpha-D-Galactopyranosidase
Alpha-Gal 1000
Validase AGS
alpha-D-Galactoside galactohydrolase
Alpha Gal 500
alpha-Galactosidase A
Sumizyme AGS

Biological Activity

[Description]:

α-Galactosidase (EC 3.2.1.22), that is, α-galactosidase, is a glycoside hydrolase that widely exists in animals, plants and microorganisms, and is often used in biochemical research. α-Galactosidase catalyzes the hydrolysis of α-1,6-linked terminal galactose residues, including galactooligosaccharides, galactomannans, and galactolipids. Catalyzes many catabolic processes including cleavage of glycoproteins, glycolipids and polysaccharides[1].

[Related Catalog]:

Research Areas >> Others

[References]

[1]. Sonu Bhatia, et al. Microbial production and biotechnological applications of α-galactosidase. Int J Biol Macromol. 2020 May 1;150:1294-1313.

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
324.4±22.0 °C at 760 mmHg

[ Molecular Formula ]:
C₉H₅ClN₂O

[ Molecular Weight ]:
192.602

[ Flash Point ]:
150.0±22.3 °C

[ Exact Mass ]:
192.009033

[ LogP ]:
2.12

[ Appearance of Characters ]:
buffered aqueous solution

[ Vapour Pressure ]:
0.0±0.7 mmHg at 25°C

[ Index of Refraction ]:
1.663

[ Storage condition ]:
2-8°C

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
36/37-26

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Articles

High throughput screening for inhibitors of alpha-galactosidase.

Curr. Chem. Genomics 4 , 67-73, (2011)

Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in α-galactosidase A (GLA), which catalyzes the hydrolysis of terminal α-galactosyl groups from glycosphingolipids, s...

Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A.

Am. J. Physiol. Gastrointest. Liver Physiol. 306(2) , G140-6, (2014)

A defect in the gene for the lysosomal enzyme α-galactosidase A (Gla) results in globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from cardiac and cerebrovascular...

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.

PLoS ONE 7(10) , e47805, (2012)

Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotr...